Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.
British journal of haematology
LYRA; bortezomib; cyclophosphamide; daratumumab; multiple myeloma
This United States community study evaluated the combination of daratumumab, bortezomib, cyclophosphamide and dexamethasone (D-VCd) in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). Patients received 4-8 induction cycles of bortezomib 1·5 mg/m
Yimer, Habte; Melear, Jason; Faber, Edward; Bensinger, William; Burke, John M; Narang, Mohit; Stevens, Don; Gunawardena, Sriya; Lutska, Yana; Qi, Keqin; Ukropec, Jon; Qi, Ming; Lin, Thomas S; and Rifkin, Robert M, "Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study." (2019). Articles, Abstracts, and Reports. 1298.